Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Budesonide mixed with surfactant did not affect neurodevelopmental outcomes at 6 or 18 months corrected age in observational cohorts

Journal of Perinatology volume 41, pages 1681–1689 (2021)Cite this article

Subjects

Abstract

Background

The addition of budesonide to surfactant in very-low-birth-weight infants with less severe RDS decreased bronchopulmonary dysplasia (BPD) severity. Long-term neurodevelopmental follow-up was needed to monitor for systemic effects of budesonide.

Methods

Infants ≤1250 g who received intratracheal budesonide (0.25 mg/kg) with surfactant (n = 173) were compared to a historical cohort who received surfactant alone (n = 294). Peabody Developmental Motor Scales II at 4–6 months corrected age and Bayley Scales of Infant & Toddler Development III at 18–22 months corrected age were compared.

Results

There were no differences in muscle tone or motor skills by Peabody exam. There were no differences in the cognitive, language, or motor domains between cohorts on Bayley III.

Conclusions

In a cohort of infants treated with budesonide mixed with surfactant, there were no differences in developmental outcomes at 4–6 months or 18–22 months corrected age.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Correlation of Bayley III scores with Peabody II scores.

Similar content being viewed by others

References

  1. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA. 2015;314:1039–51.

    Article  CAS  Google Scholar 

  2. Horbar JD, Edwards EM, Greenberg LT, Morrow KA, Soll RF, Buus-Frank ME, et al. Variation in performance of neonatal intensive care units in the United States. JAMA Pediatr. 2017;171:e164396.

    Article  Google Scholar 

  3. Johnson S, Moore T, Marlow N. Using the Bayley-III to assess neurodevelopmental delay: which cut-off should be used? Pediatr Res. 2014;75:670–4.

    Article  Google Scholar 

  4. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. Am J Respir Crit Care Med. 2011;183:1715–22.

    Article  Google Scholar 

  5. Ambalavanan N, Carlo WA, D’Angio CT, McDonald SA, Das A, Schendel D, et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics. 2009;123:1132–41.

    Article  Google Scholar 

  6. Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet. 2016;387:1827–36.

    Article  CAS  Google Scholar 

  7. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;10:CD001146.

    PubMed  Google Scholar 

  8. Bassler D, Shinwell ES, Hallman M, Jarreau PH, Plavka R, Carnielli V, et al. Long-term effects of inhaled budesonide for bronchopulmonary dysplasia. N. Engl J Med. 2018;378:148–57.

    Article  CAS  Google Scholar 

  9. Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2016;193:86–95.

    Article  CAS  Google Scholar 

  10. Kothe TB, Sadiq FH, Burleyson N, Williams HL, Anderson C, Hillman NH. Surfactant and budesonide for respiratory distress syndrome: an observational study. Pediatr Res. 2020;87:940–5.

    Article  CAS  Google Scholar 

  11. Bassler D, Plavka R, Shinwell ES, Hallman M, Jarreau PH, Carnielli V, et al. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N. Engl J Med. 2015;373:1497–506.

    Article  CAS  Google Scholar 

  12. Shinwell ES, Portnov I, Meerpohl JJ, Karen T, Bassler D. Inhaled corticosteroids for bronchopulmonary dysplasia: a meta-analysis. Pediatrics. 2016;138:1–10.

    Article  Google Scholar 

  13. van den Brink KI, Boorsma M, Staal-van den Brekel AJ, Edsbacker S, Wouters EF, Thorsson L. Evidence of the in vivo esterification of budesonide in human airways. Br J Clin Pharmacol. 2008;66:27–35.

    Article  Google Scholar 

  14. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin therapeutics. 2003;25:C28–41.

    Article  CAS  Google Scholar 

  15. Huang LT, Yeh TF, Kuo YL, Chen PC, Chen CM. Effect of surfactant and budesonide on the pulmonary distribution of fluorescent dye in mice. Pediatrics Neonatol. 2015;56:19–24.

    Article  Google Scholar 

  16. Ricci F, Catozzi C, Ravanetti F, Murgia X, D’Alo F, Macchidani N, et al. In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration. Pediatr Res. 2017;82:1056–63.

    Article  CAS  Google Scholar 

  17. Li L, Yang C, Feng X, Du Y, Zhang Z, Zhang Y. Effects of intratracheal budesonide during early postnatal life on lung maturity of premature fetal rabbits. Pediatr Pulmonol. 2018;53:28–35.

    Article  Google Scholar 

  18. Kothe TB, Royse E, Kemp MW, Schmidt A, Salomone F, Saito M, et al. Effects of budesonide and surfactant in preterm fetal sheep. Am J Physiol Lung Cell Mol Physiol. 2018;315:L193–L201.

    Article  CAS  Google Scholar 

  19. Kothe TB, Kemp MW, Schmidt A, Royse E, Salomone F, Clarke MW, et al. Surfactant plus budesonide decreases lung and systemic inflammation in mechanically ventilated preterm sheep. Am J Physiol Lung Cell Mol Physiol. 2019;316:L888–L893.

    Article  CAS  Google Scholar 

  20. Roberts JK, Stockmann C, Dahl MJ, Albertine KH, Egan E, Lin Z, et al. Pharmacokinetics of budesonide administered with surfactant in premature lambs: implications for neonatal clinical trials. Curr Clin Pharm. 2016;11:53–61.

    Article  CAS  Google Scholar 

  21. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr. 2014;165:1258–60.

    Article  CAS  Google Scholar 

  22. Brouwer MJ, Kersbergen KJ, van Kooij BJM, Benders M, van Haastert IC, Koopman-Esseboom C, et al. Preterm brain injury on term-equivalent age MRI in relation to perinatal factors and neurodevelopmental outcome at two years. PLoS One. 2017;12:e0177128.

    Article  Google Scholar 

  23. Rogers EE, Hintz SR. Early neurodevelopmental outcomes of extremely preterm infants. Semin Perinatol. 2016;40:497–509.

    Article  Google Scholar 

  24. Claassen CC, Hillman NH, Brown K, Williams HL, Strand ML. Comparison of bubble CPAP devices using RAM cannula for extubation failure in very low birth weight infants: randomized and cohort studies. Neonatology. 2019;115:28–35.

    Article  Google Scholar 

  25. Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Early CPAP versus surfactant in extremely preterm infants. N. Engl J Med. 2010;362:1970–9.

    Article  CAS  Google Scholar 

  26. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116:1353–60.

    Article  Google Scholar 

  27. Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE, et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J Pediatr. 2017;181:12–28. e11

    Article  Google Scholar 

  28. Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr. 2018;197:300–8.

    Article  Google Scholar 

  29. Quinn GE, Ying GS, Bell EF, Donohue PK, Morrison D, Tomlinson LA, et al. Incidence and early course of retinopathy of prematurity: secondary analysis of the postnatal growth and retinopathy of prematurity (G-ROP) study. JAMA Ophthalmol. 2018;136:1383–9.

    Article  Google Scholar 

  30. Connolly BH, McClune NO, Gatlin R. Concurrent validity of the Bayley-III and the Peabody Developmental Motor Scale-2. Pediatr Phys Ther. 2012;24:345–52.

    Article  Google Scholar 

  31. Schmidt B, Roberts RS, Davis PG, Doyle LW, Asztalos EV, Opie G, et al. Prediction of late death or disability at age 5 years using a count of 3 neonatal morbidities in very low birth weight infants. J Pediatr. 2015;167:982–6. e982

    Article  Google Scholar 

  32. Connolly BH, Dalton L, Smith JB, Lamberth NG, McCay B, Murphy W. Concurrent validity of the Bayley Scales of Infant Development II (BSID-II) Motor Scale and the Peabody Developmental Motor Scale II (PDMS-2) in 12-month-old infants. Pediatr Phys Ther. 2006;18:190–6.

    Article  Google Scholar 

  33. Gill K, Osiovich A, Synnes A, Agnew JA, Grunau RE, Miller SP, et al. Concurrent validity of the Bayley-III and the Peabody Developmental Motor Scales-2 at 18 months. Phys Occup Ther Pediatr. 2019;39:514–24.

    Article  Google Scholar 

  34. Spittle A, Orton J, Anderson PJ, Boyd R, Doyle LW. Early developmental intervention programmes provided post hospital discharge to prevent motor and cognitive impairment in preterm infants. Cochrane Database Syst Rev. 2015: CD005495.

  35. Veldman SLC, Santos R, Jones RA, Sousa-Sa E, Okely AD. Associations between gross motor skills and cognitive development in toddlers. Early Hum Dev. 2019;132:39–44.

    Article  Google Scholar 

  36. Anderson PJ, De Luca CR, Hutchinson E, Roberts G, Doyle LW, Victorian Infant Collaborative G. Underestimation of developmental delay by the new Bayley-III Scale. Arch Pediatr Adolesc Med. 2010;164:352–6.

    Article  Google Scholar 

  37. Adams-Chapman I, Heyne RJ, DeMauro SB, Duncan AF, Hintz SR, Pappas A, et al. Neurodevelopmental impairment among extremely preterm infants in the neonatal research network. Pediatrics. 2018;141:1–11.

    Article  Google Scholar 

  38. Juul SE, Comstock BA, Wadhawan R, Mayock DE, Courtney SE, Robinson T, et al. A randomized trial of erythropoietin for neuroprotection in preterm infants. N. Engl J Med. 2020;382:233–43.

    Article  CAS  Google Scholar 

  39. Claassen CC, Strand ML, Williams HL, Hillman NH. Use of the RAM cannula with early bubble continuous positive airway pressure requires higher pressures: clinical and in vitro evaluations. Am J Perinatol. 2020. Online ahead of print.

Download references

Acknowledgements

Grant Support: Department of Pediatrics and SSM Cardinal Glennon Foundation.

Author information

Authors and Affiliations

  1. Division of Neonatal-Perinatal Medicine, Department of Pediatrics, Saint Louis University School of Medicine, Cardinal Glennon Children’s Hospital, St. Louis, MO, USA

    Connie D. Anderson, T. Brett Kothe, Justin B. Josephsen, Farouk H. Sadiq & Noah H. Hillman

  2. Division of Neonatology, Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, TN, USA

    T. Brett Kothe

  3. SSM Health Cardinal Glennon Children’s Hospital, St. Louis, MO, USA

    Nikki Burleyson & Howard L. Williams

Authors
  1. Connie D. Anderson
    View author publications

    Search author on:PubMed Google Scholar

  2. T. Brett Kothe
    View author publications

    Search author on:PubMed Google Scholar

  3. Justin B. Josephsen
    View author publications

    Search author on:PubMed Google Scholar

  4. Farouk H. Sadiq
    View author publications

    Search author on:PubMed Google Scholar

  5. Nikki Burleyson
    View author publications

    Search author on:PubMed Google Scholar

  6. Howard L. Williams
    View author publications

    Search author on:PubMed Google Scholar

  7. Noah H. Hillman
    View author publications

    Search author on:PubMed Google Scholar

Contributions

Drs. Anderson and Hillman conceptualized and designed the study, extracted the data, analyzed the data, drafted the initial manuscript, and reviewed and revised the manuscript. Drs. Sadiq, Kothe, Josephsen, and Burleyson conceptualized and designed the study, extracted the data, and reviewed and revised the manuscript. Mr. Williams designed the study, extracted the data, and reviewed and revised the manuscript. All authors approved the final manuscript as submitted

Corresponding author

Correspondence to Noah H. Hillman.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anderson, C.D., Kothe, T.B., Josephsen, J.B. et al. Budesonide mixed with surfactant did not affect neurodevelopmental outcomes at 6 or 18 months corrected age in observational cohorts. J Perinatol 41, 1681–1689 (2021). https://doi.org/10.1038/s41372-021-01066-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41372-021-01066-x

This article is cited by

Search

Advanced search

Quick links